Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell … – News-Medical.net
|
Bortezomib reduces GVHD, boosts survival for patients receiving stem–cell …
News-Medical.net Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem–cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber … Stem Cell Transplants can be improved by New Drug RegimenTopNews United States Rx Improved Stem Cell Transplant Success and SurvivaldailyRx |
